Constellation Pharmaceuticals Inc (NASDAQ:CNST) has coverage initiated with a Overweight rating

0

Analyst Ratings For Constellation Pharmaceuticals Inc (NASDAQ:CNST)

Today, JPMorgan Chase & Co. initiated coverage on Constellation Pharmaceuticals Inc (NASDAQ:CNST) with a Overweight.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Constellation Pharmaceuticals Inc (NASDAQ:CNST) is Buy with a consensus target price of $21.00 per share, a potential 113.20% upside.

Some recent analyst ratings include

  • 8/13/2018-Constellation Pharmaceuticals Inc (NASDAQ:CNST) has coverage initiated with a Overweight rating
  • 8/13/2018-Constellation Pharmaceuticals Inc (NASDAQ:CNST) has coverage initiated with a Outperform rating
  • 8/13/2018-Constellation Pharmaceuticals Inc (NASDAQ:CNST) has coverage initiated with a Outperform rating and $21.00 price target


    Recent Trading Activity for Constellation Pharmaceuticals Inc (NASDAQ:CNST)
    Shares of Constellation Pharmaceuticals Inc closed the previous trading session at 9,85 −0,020 0,20 % with 9.35 shares trading hands.